Latest Manufacturing News

Impact Minerals’ 50%-owned Alluminous Pty Ltd advances its proprietary HiPurA® High Purity Alumina technology with new leadership and pilot plant commissioning, attracting strong customer interest.

Aquirian’s subsidiary TBS Mining Solutions has secured a $4.2 million binding term sheet with Papyrus Australia to manufacture biodegradable Collar Keeper® products, marking a significant step towards greener mining operations.

Fletcher Building reported a $419 million net loss for FY25 on softer demand and legacy costs but halved its net debt to $999 million through strategic capital management and divestments.

James Hardie Industries reported a 9% decline in Q1 FY26 net sales to $900 million, while successfully completing its AZEK acquisition, setting the stage for expanded market reach and product offerings. The company adjusted its FY26 guidance to reflect softer North American demand but remains focused on long-term growth.

XRF Scientific Limited reported a record profit for FY25, driven by strong mining sector demand and international sales growth, alongside strategic acquisitions that bolster its market position.

Argent BioPharma has signed a binding term sheet to acquire key assets from AusCann Group Holdings, significantly expanding its clinical pipeline, intellectual property, and European manufacturing and distribution capabilities ahead of a planned US stock exchange listing.

XRF Scientific has reported a record full-year result for FY2025, with net profit rising 17% to $10.4 million and a 15% increase in its fully franked dividend. Strong global mining demand and recurring revenue streams underpin the company’s growth.

Wide Open Agriculture has launched a pre-feasibility study for a large-scale lupin protein facility in Western Australia, aiming to establish a new global food category and reduce production costs. This move marks a pivotal step toward commercial scale and global leadership in sustainable plant-based proteins.

ARB Corporation Limited reported a 5.3% increase in sales revenue to $729.9 million for FY2025, driven by strong export growth and steady domestic sales, while profit after tax declined 5%. The company declared a special fully franked dividend amid ongoing US expansion efforts.

AdAlta Limited outlines its innovative 'East to West' cellular immunotherapy approach, in-licensing Asian CAR-T assets and progressing clinical trials in Australia to unlock value. The company also seeks partners for its anti-fibrotic and anti-malarial protein therapeutics.

BHP has reported record copper and iron ore production for FY25, delivering robust financial results despite a challenging commodity price environment. The company is advancing key growth projects and maintaining strong capital discipline.

CSL Limited reported solid FY25 financials with 5% revenue growth and announced a strategic transformation including a $500 million annual cost saving target and plans to spin off its vaccine business, CSL Seqirus, as a separate ASX-listed entity.